Changes in ctDNA can predict long-term outcomes in certain patients with metastatic CRC on immune checkpoint inhibitors.

Using ctDNA test results to guide adjuvant treatment with pembrolizumab can provide benefits in patients with dMMR solid tumors, data suggest.

MOMA Therapeutics, a clinical-stage biopharmaceutical company discovering and developing a new generation of precision therapeutics, today announced that the first patient has been dosed in its Phase ...

The global metastatic colorectal cancer (mCRC) market is expanding rapidly, fueled by rising colorectal cancer cases, therapy advancements, and a focus on patient outcomes. mCRC, a severe cancer form, ...

Leading global doctors, researchers, and lawyers have joined forces with patient representatives and created the first-ever information guide to better support and protect patients across the world ...

When surgeons dissect tissue to remove a tumor or make a repair they must work cautiously, relying on electrophysical monitors and their own anatomical knowledge to avoid cutting nerves, which could ...

ATOMIC is the first phase 3 trial to demonstrate the benefit of adding immunotherapy in the adjuvant setting for colon cancer. The results support the integration of atezolizumab into first-line ...

The CheckMate 8HW trial (NCT04008030) 2 evaluated the combination of nivolumab (Opdivo) with ipilimumab (Yervoy) as a first-line treatment for adult and pediatric patients aged 12 years and older with ...